Vemurafenib, a targeted kinase inhibitor of the B-Raf protein variant produced by a V600E point mutation in BRAF, has been shown to reduce tumor burden and to improve overall survival in melanoma patients [1]. This evidence concerns the gene BRAF and neoplasm.